Health care? More like health scare!
Every day is Halloween for pharma marketers... More
Every day is Halloween for pharma marketers... More
Why is clinical research such a mess? And how can we clean it up? More
How do we balance evidence and patient preferences in the intensifying statin debate? More
Medical overuse is just as much a problem in children's health care as it is for adults, so why isn't there more recognition of this issue? More
Fee-for-service drives overuse and high costs, but what's the alternative? Maryland may have the answer. More
Researchers and advocates are up in arms over a new review of Hepatitis C treatments. But look who's funding each side... More
Rewarding doctors for following quality measures should be a win-win, but there's one problem- many of these measures don't actually make patients healthier. More
From industry payments to kickbacks, corruption is everywhere in health care. And it comes at a high cost to patient safety. More
An Interview with Patty Gabow Keeping the Patient at the Center in Hospital Administration Patricia A. Gabow, MD, MACP is Professor Emerita of Medicine at the University of Colorado and the former CEO of Denver Health. She is the author of more than 130 articles, 36 books and book chapters, and a recent book, The Lean Prescription: Powerful […] More
What do you do when your patient’s well-being is threatened by rules beyond your control? More
With the Right Care Series, published by The Lancet in 2017, the Lown Institute launched a global effort to assess the scope of overuse and underuse and place these twin failings at the center of health strategies everywhere to achieve the right care for all people. The Institute organized a team of 27 international experts from nine countries and 21 institutions. More
When Julie Martinez was diagnosed with thyroid cancer, she started doing research on overdiagnosis, and was shocked by what she found... More
The page that lists blog posts. This text will not be visible. More
The Lown Institute is a nonpartisan think tank advocating bold ideas for a just and caring system for health. More
When researchers and the press started asking about duloxetine, the FDA didn’t scour its database and go public. It kept quiet. More